Dr Lalchandani Labs closes trading window from Oct 1 for H1FY27 results

0 min read | Published on 30 Sept 2026, 08:30 PM |Updated on 30 Sept 2026, 08:30 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Trading window closed from October 1, 2026
Restriction applies to H1FY27 results declaration
Window reopens 48 hours after results release
Board meeting date to be announced separately

*this image is generated using AI for illustrative purposes only.

Dr Lalchandani Labs Ltd. has closed its trading window for securities dealing starting October 1, 2026. This restriction applies to directors, promoters, designated persons, and connected persons in compliance with insider trading regulations.

The closure is mandated under the SEBI (Prohibition of Insider Trading) Regulations, 2015, and BSE Circular No. LIST/COMP/01/2019-20 dated April 2, 2019. The window will reopen 48 hours after the declaration of un-audited financial results for the half-year ended September 30, 2026.

Compliance and Timeline

The company informed BSE Limited that the trading restriction period begins on Thursday, October 1, 2026. The specific date for the Board Meeting to consider these financial results will be communicated separately in due course.

Event	Date	Status
Trading Window Closure Start	October 1, 2026	Effective
Period Covered	H1FY27 (Apr-Sep 2026)	Pending Results
Window Reopening	48 hours post-declaration	Scheduled

The intimation was signed by Arjan Lalchandani, Managing Director, on September 30, 2026. No financial figures or performance metrics were disclosed in this regulatory filing.

Historical Stock Returns for Dr Lalchandani Labs

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-4.97%	-11.78%	-10.17%	0.0%	0.0%	-59.11%

How might the upcoming H1FY27 financial results influence Dr Lalchandani Labs' stock volatility once the trading window reopens?

What specific operational or regulatory developments in the pharmaceutical sector could impact the company's half-year performance metrics?

Will the delay in announcing the Board Meeting date signal any internal restructuring or strategic shifts within the management team?

Dr Lalchandani Labs

View Company Insights

View All News

Dr Lalchandani Labs AGM for FY26 extended to Dec 31 due to health issues

0 min read | Published on 17 Sept 2026, 08:33 PM |Updated on 17 Sept 2026, 08:33 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Dr Lalchandani Labs AGM for FY26 postponed to on or before December 31, 2026
ROC Delhi granted three-month extension citing Chairperson's ill health
Original deadline was September 30, 2026; application filed September 15
Company advised to ensure timely compliance with Companies Act provisions

*this image is generated using AI for illustrative purposes only.

Dr Lalchandani Labs has obtained regulatory approval to postpone its Annual General Meeting (AGM) for FY26 until December 31, 2026. The company cited the ill health of its Chairperson as the primary reason for seeking the extension.

The Registrar of Companies (ROC), Delhi, granted a three-month extension under Section 96(1) of the Companies Act, 2013. The AGM was originally scheduled to be held on or before September 30, 2026. The company submitted its application on September 15, 2026, and received approval on September 17, 2026.

Regulatory Compliance

The ROC order mandates that the company hold the meeting at the earliest possible date but no later than December 31, 2026. The regulator advised the company to ensure timely compliance with statutory provisions in future filings.

The exact date, venue, and notice for the rescheduled AGM will be communicated separately. Mohit Lalchandani, Whole Time Director, signed the announcement confirming the regulatory approval.

Historical Stock Returns for Dr Lalchandani Labs

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-4.97%	-11.78%	-10.17%	0.0%	0.0%	-59.11%

How might the prolonged absence of the Chairperson due to ill health impact the company's strategic decision-making and board stability in the short term?

Will the delay in holding the AGM affect the timeline for declaring dividends or approving key financial resolutions for FY26?

Are there any potential implications for investor confidence or stock liquidity given the regulatory extension and leadership health concerns?

Dr Lalchandani Labs

View Company Insights

View All News